An update on the long-term safety experience of Ustekinumab: Results from the psoriasis clinical development program with up to four years of follow-up

Kristian Reich*, Kim A. Papp, Christopher E.M. Griffiths, Philippe O. Szapary, Newman Yeilding, Yasmine Wasfi, Elyssa Ott, Ming Chun Hsu, Mark Lebwohl, Kenneth B Gordon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Fingerprint

Dive into the research topics of 'An update on the long-term safety experience of Ustekinumab: Results from the psoriasis clinical development program with up to four years of follow-up'. Together they form a unique fingerprint.

Medicine & Life Sciences